Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2-Low Breast Carcinoma”

95 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 95 results

Not applicableStudy completedNCT06386263
What this trial is testing

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
AstraZeneca 22
Large-scale testing (Phase 3)Not Yet RecruitingNCT06561607
What this trial is testing

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 542
Testing effectiveness (Phase 2)Looking for participantsNCT06207734
What this trial is testing

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Testing effectiveness (Phase 2)Looking for participantsNCT06298084
What this trial is testing

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Who this might be right for
Breast Cancer MetastaticHER2-positive Metastatic Breast CancerHER2 Low Breast Carcinoma+1 more
Gustave Roussy, Cancer Campus, Grand Paris 152
Early research (Phase 1)Looking for participantsNCT05461768
What this trial is testing

BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 26
Testing effectiveness (Phase 2)Looking for participantsNCT06411457
What this trial is testing

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 20
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06975462
What this trial is testing

A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases

Who this might be right for
Breast Cancer Metastatic
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 30
Early research (Phase 1)Ended earlyNCT02598427
What this trial is testing

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Who this might be right for
HER2 Positive Untreated Metastatic Breast CancerAsymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Kimberly Blackwell 1
Not applicableEnded earlyNCT05592483
What this trial is testing

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 78
Not applicableStudy completedNCT05913440
What this trial is testing

HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

Who this might be right for
Breast Cancer
AstraZeneca 1,669
Testing effectiveness (Phase 2)Looking for participantsNCT07498478
What this trial is testing

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Who this might be right for
Breast Cancer
TransThera Sciences (Nanjing), Inc. 94
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07497386
What this trial is testing

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Who this might be right for
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151586
What this trial is testing

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsNeoplasm MetastasisHER 2 Low-expressing Breast Cancer
UNICANCER 260
Early research (Phase 1)Study completedNCT00821054
What this trial is testing

Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 24
Testing effectiveness (Phase 2)Looking for participantsNCT06263543
What this trial is testing

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Who this might be right for
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+2 more
Reshma L. Mahtani, D.O. 75
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Not applicableStudy completedNCT07211451
What this trial is testing

Axillary Nodal Burden in HER2+ and TNBC

Who this might be right for
Breast Cancer
Gangnam Severance Hospital 1,571
Load More Results